The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma

Not yet recruiting

• Conditions: Asthma; Corticosteroid

• Registration Number: NCT05750797
• Lead Sponsor: Joon Young Choi

Brief Summary

The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database.

Detailed Description

South Korea has a compulsory universal health insurance system for entire Korean population. The number of people who are covered was more than 50 million. The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators have performed many studies regarding asthma in South Korea. In this study, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database.

Primary outcome was the OCS prescription in all patients with asthma. Secondary outcome was OCS prescription according to the asthma severity, age, sex, socioeconomic status and the type of hospital.

Inclusion criteria was 1) Age ≥ 15 years; 2) ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis; 3) use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).

Study Timeline

• Study First Submitted: 2023-02-20
• Study First Submitted QC: 2023-02-20
• Status Verified: 2023-03
• Study Start: 2023-03-01
• Study First Posted: 2023-03-02
• Last Update Submitted: 2023-03-03
• Last Update Posted: 2023-03-06
• Primary Completion: 2023-12
• Study Completion: 2023-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 800000

Inclusion Criteria

• Age ≥ 15 years;
• ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis
• use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).

Exclusion Criteria

• Those who are not in the insurance system

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
OCS prescription rates	1-year	Analysis the OCS prescription in all patients with asthma

Secondary Outcome Measures

Name	Time	Method
OCS prescription according to the asthma severity	1-year
OCS prescription according to sex	1-year
OCS prescription according to socioeconomic status	1-year
OCS prescription according to the type of hospital	1-year
OCS prescription according to age	1-year

Trial Locations

Locations (1)

Incheon St. Mary's Hospital; 🇰🇷 Incheon, Gyeongki, Korea, Republic of